Stockreport

Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Diseas...

Anavex Life Sciences Corp.  (AVXL) 
NASDAQ:AMEX Investor Relations: anavex.com/share-data
PDF NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced its participation as a key industry [Read more]